Gentian Diagnostics: Third quarter 2025 report

23 Oct 2025 08:00 CEST

Moss, 23 October 2025

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the third quarter of 2025.

Highlights include:
Sales of NOK 41.8 million in 3Q25, up 28% vs 3Q24 (31% organic growth). YTD 2025
sales of NOK 129.9 million up 19% (19% organic growth) versus the first nine
months of 2024.

EBITDA of NOK 8.4 million in 3Q25 versus NOK 5.0 million in 3Q24. For the first
nine months of 2025 the EBITDA is NOK 24.1 million versus 16.5 million for the
same period last year.

Gross margin of 56% in 3Q25 versus 52% in 3Q24.

Sales of Cystatin C increased with 73% in 3Q25 compared to 3Q24 driven by strong
performance in the US.

YTD sales to the US were NOK 21.7 million vs. NOK 8.1 million for the same
period in 2024, partly due to a shift in warehouse for one of our largest
customers. NOK 2.3 million or 10% of sales comes from new accounts acquired in
2025.

NT-proBNP advancements moving closer to final stages of verification. The
timeline for full commercial launch is now estimated to take place during 4Q
2026.

The development project for a major IVD company entered successfully the next
development phase (from proof-of-concept to optimization).

In 3Q several study sites have been activated and approximately 70 patients
enrolled in the JIA COMPASS study that evaluates the diagnostic and prognostic
use of GCAL in children with juvenile idiopathic arthritis (JIA).


Webcast
The company will present the results today at 09.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website:

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation.

IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business
controller at Gentian Diagnostics ASA, on 23 October 2025 at 08:00 CEST.


About Gentian
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within
immunoassays, specifically for infections, inflammation, kidney failure and
congestive heart failure. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian Diagnostics is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

More information:
Access the news on Oslo Bors NewsWeb site

657758_GDASA Q3 25 presentation.pdf
657758_GDASA Interim report 3Q 2025.pdf